Market Intelligence, Clinical Progress, and High-Purity Reagents for MAPKAPK5 (MK5) Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAPKAPK5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAPKAPK5 Recombinant Protein (Active Kinase / Mutant K51R) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View MAPKAPK5 Products |
| Gene Delivery | MAPKAPK5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression. |
View MAPKAPK5 Products |
| Benchmark Ab | Anti-MAPKAPK5 Recombinant Antibody High-affinity positive control for Western Blot and IP validation. |
View MAPKAPK5 Products |
| Validator | MAPKAPK5 siRNA Set Target-specific knockdown verification in cellular assays. |
View MAPKAPK5 Products |
| Related Target A | MAPKAPK2 (MK2) Critical homolog for selectivity screening to avoid off-target cardiotoxicity. |
View MAPKAPK2 Products |
| Related Target B | MAPK6 (ERK3) Upstream atypical MAPK activator regulating MAPKAPK5 stability and localization. |
View MAPK6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against highly homologous MK2/MK3 kinases | Human MAPKAPK2, MAPKAPK3, and MAPKAPK5 panel proteins strictly verified by mass spectrometry and sequence analysis. |
| Kinase-dead control validation | Sequence-verified K51R inactive mutant protein available with theoretical MW validation. |
| Lack of reliable positive controls | Recombinant benchmark antibodies and validated siRNA sets included for phenotypic assay baseline. |
| False positives in high-throughput screening | High purity (>95%) and low endotoxin control ensure low background noise in enzymatic assays. |
Live MAPKAPK5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAPKAPK5 (MK5) therapeutics is expanding beyond its classical role in inflammatory pathways into oncology and fibrotic diseases. As an atypical MAPK-activated protein kinase, MAPKAPK5 is regulated by both p38 and ERK3/ERK4 pathways, making it a unique node in cellular signaling. While early drug discovery focused on broad p38 pathway inhibitors, high toxicity led to clinical failures. The next wave of R&D is targeting MAPKAPK5 specifically to bypass systemic p38 inhibition side effects.
Current pipelines are heavily focused on highly selective small-molecule inhibitors. Key therapeutic areas include colorectal cancer, where MAPKAPK5 acts as a downstream effector of oncogenic KRAS, and idiopathic pulmonary fibrosis (IPF), where it mediates myofibroblast differentiation. Developing molecules that can selectively inhibit MAPKAPK5 without cross-reacting with its close homolog MAPKAPK2 (MK2) remains the primary technical hurdle in the field.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Boehringer Ingelheim, Academic Consortia | Colorectal Cancer, Fibrosis | Selectivity Assay (Need Mutant vs WT Proteins & MK2/MK3 Panels) |
| PROTAC / Degraders | Biotech Startups | Oncology, Rheumatoid Arthritis | Target Engagement (Need high-purity full-length proteins for ternary complex assays) |
| siRNA Therapeutics | RNAi Developers | Dermatological Disorders, Fibrosis | In vitro knockdown verification (Need Lentivirus-driven stable cell lines) |